XBiotech (XBIT) Research & Development (2014 - 2026)
XBiotech (XBIT) posted quarterly Research & Development of $25.4 million for Q4 2025, up 224.23% year-over-year from $7.8 million in Q4 2024, and up 399.17% quarter-over-quarter from $5.1 million in Q3 2025.
XBiotech (XBIT) Research & Development (2014 - 2026) Analysis & Trends
XBiotech's Research & Development history runs 12 years deep, the most recent figure standing at $25.4 million for Q4 2025.
- In Q4 2025, Research & Development rose 224.23% year-over-year to $25.4 million; the TTM figure through Dec 2025 stood at $47.4 million (up 25.52% YoY), while the FY2025 annual figure was $47.4 million, up 25.51% from the prior year.
- Research & Development for Q4 2025 stood at $25.4 million, up from $5.1 million in the prior quarter.
- The five-year high for Research & Development was $25.4 million in Q4 2025, with the low at $4.6 million in Q1 2021.
- The 5-year median for Research & Development is $7.7 million (2023), against an average of $8.9 million.
- The sharpest annual moves came in 2021 and 2025: Research & Development soared 301.21% in 2021, then slumped 58.9% in 2025.
- XBiotech's Research & Development stood at $8.8 million in 2021, then slipped by 16.68% to $7.3 million in 2022, then gained by 6.66% to $7.8 million in 2023, then climbed by 0.22% to $7.8 million in 2024, then jumped by 224.23% to $25.4 million in 2025.
- Business Quant data shows XBIT's Research & Development at $25.4 million in Q4 2025, $5.1 million in Q3 2025, and $5.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.30 Mn |
| Dec 31, 2025 | 25.36 Mn |
| Sep 30, 2025 | 5.08 Mn |
| Jun 30, 2025 | 5.34 Mn |
| Mar 31, 2025 | 11.62 Mn |
| Dec 31, 2024 | 7.82 Mn |
| Sep 30, 2024 | 7.13 Mn |
| Jun 30, 2024 | 12.98 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | 7.80 Mn |
| Sep 30, 2023 | 7.55 Mn |
| Jun 30, 2023 | 11.27 Mn |
| Mar 31, 2023 | 6.23 Mn |
| Dec 31, 2022 | 7.32 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 10.39 Mn |
| Mar 31, 2022 | 6.82 Mn |
| Dec 31, 2021 | 8.78 Mn |
| Sep 30, 2021 | 5.60 Mn |
| Jun 30, 2021 | 9.25 Mn |